Business
Novo Nordisk CEO Outlines M&A Strategy and Pipeline Growth Amid Investor Skepticism
Novo Nordisk CEO Peter Doustdar signals M&A opportunities to bolster its drug pipeline, but shares drop as investors question the pace of…
Novo Nordisk CEO Peter Doustdar signals M&A opportunities to bolster its drug pipeline, but shares drop as investors question the pace of…